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HIV-1, the cause of AIDS, is composed of four phylogenetic line-
ages, groups M, N, O, and P, each of which resulted from an in-
dependent cross-species transmission event of simian immuno-
deficiency viruses (SIVs) infecting African apes. Although groups
M and N have been traced to geographically distinct chimpanzee
communities in southern Cameroon, the reservoirs of groups O
and P remain unknown. Here, we screened fecal samples fromwest-
ern lowland (n = 2,611), eastern lowland (n = 103), and mountain
(n = 218) gorillas for gorilla SIV (SIVgor) antibodies and nucleic
acids. Despite testing wild troops throughout southern Cam-
eroon (n = 14), northern Gabon (n = 16), the Democratic Republic
of Congo (n = 2), and Uganda (n = 1), SIVgor was identified at
only four sites in southern Cameroon, with prevalences ranging
from 0.8–22%. Amplification of partial and full-length SIVgor se-
quences revealed extensive genetic diversity, but all SIVgor strains
were derived from a single lineagewithin the chimpanzee SIV (SIVcpz)
radiation. Two fully sequenced gorilla viruses from southwestern
Cameroon were very closely related to, and likely represent the
source population of, HIV-1 group P. Most of the genome of a third
SIVgor strain, from central Cameroon, was very closely related to
HIV-1 group O, again pointing to gorillas as the immediate source.
Functional analyses identified the cytidine deaminase APOBEC3G
as a barrier for chimpanzee-to-gorilla, but not gorilla-to-human, vi-
rus transmission. These data indicate that HIV-1 group O, which
spreads epidemically in west central Africa and is estimated to
have infected around 100,000 people, originated by cross-species
transmission from western lowland gorillas.
AIDS | HIV-1 | gorilla | SIVgor | zoonotic transmission
AIDS is caused by HIV-1 and HIV-2, which are derived froma clade of lentiviruses [simian immunodeficiency viruses
(SIVs)] found naturally in more than 40 species of nonhuman
primates in sub-Saharan Africa (1, 2). These SIVs mostly fall into
host-specific clades, but they have occasionally jumped species
and spread successfully in new hosts. Of particular interest,
chimpanzees (Pan troglodytes) acquired two distinct lineages of
SIV from two different monkey species; all known strains of
chimpanzee SIV (SIVcpz) are derived from a hybrid formed by
recombination between these two viruses (3). The spread of this
virus in chimpanzees appears to have occurred comparatively
recently, because only two closely related subspecies in Central
Africa are infected, whereas two other subspecies are not (4–8).
Subsequently, strains of SIVcpz from one chimpanzee subspecies
(Pan troglodytes troglodytes) have been subject to further trans-
mission both to humans, leading to HIV-1, and to western
gorillas (Gorilla gorilla), giving rise to gorilla SIV (SIVgor) (4, 9).
The limited number of strains of SIVgor characterized so far
form a single clade, but HIV-1 strains fall into four phyloge-
netically distinct groups, each of which must reflect a separate
cross-species transmission from apes (1). These four zoonotic
events have had very different outcomes. One gave rise to group
M, the cause of the AIDS pandemic, which has infected more
than 40 million people and spread across Africa and throughout
the rest of the world. At the other extreme, group N and P
viruses have only been found in small numbers of individuals
from Cameroon: group N in fewer than 20 individuals (10) and
group P in only two individuals (11, 12). Group O, although not
nearly as prevalent as group M, has nonetheless caused a sub-
stantial epidemic. Although largely restricted to west central
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Africa, group O viruses have spread through Cameroon, Gabon,
Nigeria, and other neighboring countries, and are estimated to
have infected about 100,000 individuals (13, 14).
Molecular epidemiological studies of SIVcpz have shown that
these viruses exhibit phylogeographic clustering, apparently
largely due to major rivers and other barriers that limit the mi-
gration of wild chimpanzees (4–6). This clustering has allowed us
to pinpoint the probable geographic origins of two of the human
virus clades (4). Thus, strains of SIVcpz very closely related to
HIV-1 group M have been found only in a small area in the
southeast corner of Cameroon, implicating that region as the
likely location of the chimpanzee-to-human transmission that
gave rise to the AIDS pandemic. Similarly, strains of SIVcpz very
closely related to HIV-1 group N have been found only in south-
central Cameroon, pointing to chimpanzees in the Dja Forest as
the source of this viral lineage. However, much less is known
about the origins of the two other HIV-1 groups. Group O
viruses are more closely related to SIVgor than to SIVcpz, but it
is unclear whether the immediate precursor to the human viruses
infected chimpanzees or gorillas (1, 9, 15). Group P viruses are
even more closely related to strains of SIVgor (11, 12), indicating
that they probably arose from a gorilla-to-human transmission,
but the geographic location has not been defined.
Given the chimpanzee origin of pandemic HIV-1, previous
studies have focused almost exclusively on characterizing SIVcpz
in wild-living chimpanzees (4–7). To gain greater insight into the
molecular epidemiology of SIVgor, and to learn more about the
origins of HIV-1 groups O and P, we conducted extensive surveys
of wild living gorillas. We screened western lowland gorillas
across a large part of their geographic range in southern
Cameroon and Gabon, and also sampled both lowland and
mountain subspecies of the eastern gorilla (Gorilla beringei).
Although eastern and western gorillas likely diverged before the
origin of SIVgor, eastern gorillas may have independently ac-
quired SIV, because they share their habitat with the second
chimpanzee subspecies, the eastern chimpanzee (Pan troglodytes
schweinfurthii), which is widely and commonly infected with
SIVcpz (6). Finally, to gain insight into potential barriers to
cross-species transfers, we investigated the role of the host
restriction factor apolipoprotein B mRNA editing enzyme,
catalytic polypeptide-like 3G (APOBEC3G) in inhibiting ape-
to-ape, as well as ape-to-human, SIV transmission.
Results
SIVgor Infection Is Restricted to Western Lowland Gorillas in Southern
Cameroon. Previous molecular epidemiological studies of SIVgor
were limited to field sites in Cameroon and the Democratic
Republic of Congo (DRC) (16). To determine the prevalence
and geographic distribution of this infection in western gorillas
(G. gorilla), we collected additional fecal samples from southern
Cameroon (n = 1,696) and extended our survey to 16 field sites
in Gabon (n = 915) (Fig. 1 and Table S1). We also sampled eastern
lowland gorillas (Gorilla beringei graueri) in the DRC (n = 103) and
tested two different communities of mountain gorillas (G. beringei
beringei) in the DRC and Uganda (n = 218). All fecal samples were
examined for the presence of HIV cross-reactive antibodies using
the INNO-LIA HIV I/II score confirmation test (Innogenetics),
which contains HIV-1 and HIV-2 recombinant proteins and syn-
thetic peptides coated as discrete lines on a nylon strip. This test was
previously shown to detect SIVgor infection with greater than
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Fig. 1. Geographic distribution of SIVgor in wild-living gorillas. Field sites are shown in relation to the ranges of western (G. gorilla, red) and eastern
(G. beringei, yellow) gorillas, with subspecies indicated by broken (G. g. gorilla and G. b. graueri) and solid (G. g. diehli and G. b. beringei) lines. Forested areas
are shown in dark green, whereas arid and semiarid areas are depicted in yellow and brown, respectively. Major lakes and rivers are shown in blue. Dashed
white lines indicate national boundaries. Sites where SIVgor was detected in this study are highlighted in red (yellow border), with SIVgor-positive field sites
reported previously shown in yellow (red border) (9, 16). White and gray circles indicate SIVgor-negative sites identified in this and previous studies, re-
spectively (9, 16).
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90% sensitivity (16, 17) and has even uncovered more divergent
SIV lineages from other nonhuman primate species (2). Of a
total of 2,932 gorilla fecal samples tested, 70 reacted with at least
one HIV-1 antigen. These samples came from four field sites, all
located in southern Cameroon. Samples from the remaining 10 field
sites in Cameroon and all sites in Gabon were INNO-LIA–negative,
as were all samples from both subspecies of eastern gorillas.
Analysis of 12S mitochondrial DNA sequences confirmed that
the 70 antibody-positive fecal samples were all from western
gorillas. Eighteen of these samples were too degraded to allow
microsatellite analyses, but the remaining specimens represented
16 different individuals. Although the majority of INNO-LIA–
positive samples cross-reacted with HIV-1 gp41 and/or p24 anti-
gens, a subset exhibited strong cross-reactivity with all five HIV-1
antigens (Fig. 2). Because there was no evidence of false-positive
reactivity, we tentatively classified all gorilla samples that reacted
with at least one INNO-LIA antigen as SIVgor antibody-positive.
Across the four sites with evidence of SIVgor infection, there
was substantial variation in the number and proportion of
INNO-LIA–positive samples. For example, at site BP, 48 (30%)
of 161 samples were antibody-positive, corresponding to at least
10 infected individuals. In contrast, at site LD, located 50 km
east of site BP, only a single antibody-positive sample was de-
tected among almost 150 specimens tested. At site BQ, only
nine (2%) of 435 samples were antibody-positive, and these
samples were all from a single individual. Of note, this animal
was not the same gorilla (BQ664) in which SIVgor infection was
detected in 2004 (9). At site DJ, 12 (5%) of 237 samples were
positive, corresponding to four gorillas. We estimated the
prevalence of SIVgor infection for each field site based on the
proportion of SIVgor-positive gorillas, but correcting for repeated
sampling. Screening over 1,100 western lowland gorillas, we esti-
mated an overall prevalence of 1.6% (95% confidence interval:
1.0–2.5%), ranging from less than 1% to over 20% at the four
positive field sites (Table S1).
Field observations at site BP indicated that some of the
samples came from members of two social groups. One group
likely comprised at least 12 individuals based on nest counts,
although genotyping identified only eight sampled gorillas, three
of whom were SIVgor-positive. The second group consisted of at
least 17 individuals based on nest counts and 16 individuals
based on microsatellite analyses, seven of whom were antibody-
positive. Thus, within each of these two social groups, around
40% of individuals were infected with SIVgor. At least one of
these individuals (BP-ID4) may have represented a newly ac-
quired infection, because among 12 samples collected over a 4-mo
period, only the last one was positive (Table S2). Interestingly, 31
additional individuals from site BP, which appeared not to be-
long to either of these social groups, were all SIVgor-negative.
At the other field sites where antibody-positive individuals were
found (sites BQ, LD, and DJ), samples were collected mainly
opportunistically and around feeding sites; thus, the size of the
sampled social groups could not be estimated.
In addition to antibody detection, we tested all INNO-LIA–
positive and –negative specimens from the same nesting and/or
feeding site for the presence of SIVgor viral RNA using a real-
time quantitative PCR (RT-qPCR) assay (18). Viral RNA was
detected in 33 (58%) of 57 antibody-positive samples but also in
15 (7.4%) of 204 antibody-negative samples. In these specimens,
SIVgor RNA copy numbers ranged from a few copies to more
than 1,000 copies per milliliter of RNAlater-preserved (1:1 mix-
ture; Ambion) fecal samples. Interestingly the RT-qPCR assay
identified two additional SIVgor-infected gorillas, both of which
were members of one of the two high-prevalence social groups at
the BP site (Table S2). These individuals were likely sampled
during acute infection before the onset of antibody responses,
because 236 other INNO-LIA–negative samples collected both
at SIVgor-positive (LD, n = 42; BQ, n = 69; CP, n = 37; DJ, n =
12) and SIVgor-negative (AK, n = 12; AM, n = 12; BY, n = 12;
DD, n = 4; EK, n = 12; MB, n = 12; NY, n = 12) field sites (Fig. 1)
were all RT-qPCR–negative.
High Genetic Diversity of SIVgor. To examine the genetic diversity
of SIVgor at the various collection sites, we used nested PCR
to amplify viral sequences from antibody and/or RT-qPCR–
positive samples. These analyses yielded SIVgor core protein
(gag), polymerase (pol) and envelope (env) gene sequences
from seven of the 16 antibody-positive gorillas, as well as
from the two antibody-negative but RT-qPCR–positive animals
(Table S2). Attempts to amplify viral sequences from the other
N
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Fig. 2. Detection of SIVgor antibodies in gorilla fecal samples. INNO-LIA banding patterns are shown, with molecular weight markers of HIV-1 and HIV-2
proteins indicated. IgG control lanes (n = 3) are shown on the top of each strip; plasma from HIV-1–infected (POS) and uninfected (NEG) humans were used for
controls (two left lines). Fecal samples are grouped by individuals, with a two-letter code indicating the collection site of origin (Fig. 1).
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INNO-LIA–positive individuals, including the single gorilla at
site LD, were repeatedly unsuccessful (Table S2). Phylogenetic
analyses showed that all of the newly identified SIVgor se-
quences were more closely related to each other, and to pre-
viously characterized SIVgor strains, than to SIVcpz (Fig. 3),
indicating a single chimpanzee-to-gorilla transmission at the
origin of the SIVgor lineage.
Within the SIVgor clade, there was evidence of phylogeo-
graphic clustering; for example, all seven viruses from site BP
formed a distinct clade as did previously characterized strains
from sites CP and DJ. Interestingly, the two HIV-1 group P strains
fell within the radiation of strains from the BP site, whereas the
newly derived SIVgor strain from site BQ was closely related to
HIV-1 group O in gag, but not in other genomic regions (Fig. 3).
Full-Length Genome Sequencing of SIVgor Strains Closely Related to
HIV-1 Groups O and P. To study the phylogenetic relationships of
the SIVgor strains most closely related to HIV-1 groups O and P,
we subjected three samples to whole-genome analysis. The
concatenated fecal consensus sequences of SIVgor-BPID1,
SIVgor-BPID15, and SIVgor-BQID2 were 9,029 bp, 9,012 bp,
and 9,241 bp in length, respectively. All three viruses exhibited
the same genomic organization as other members of the HIV-1/
SIVcpz lineage, encoding a viral protein U (vpu) gene and
nonoverlapping env and negative regulatory factor (nef) genes.
Phylogenetic analyses of deduced Gag, Pol, and concatenated
Env/Nef protein sequences showed that the two fully sequenced
BP site strains, as well as two other BP site viruses (SIVgor-
BPID2 and SIVgor-BPID3) for which Gag and/or Pol sequences
were available, were very closely related to HIV-1 group P (Fig.
4). In contrast to the analyses based on short genomic fragments
(Fig. 3), the single site BQ strain (SIVgor-BQID2) was found to
cluster with HIV-1 group O in all three trees derived from full-
length protein sequences (Fig. 4).
The discordant positions of BQID2 in phylogenies derived
from different genomic regions suggested a recombinant history.
To examine the full-length sequences for evidence of recom-
bination, the newly derived SIVgor sequences were compared
with previously reported HIV-1, SIVcpz, and SIVgor genome
sequences using similarity plot and bootstrap analyses for suc-
cessive genomic regions, scanning along the alignment. SIVgor
strains BPID1 and BPID15 consistently clustered with each
other and with the two HIV-1 group P strains, across the entire
genome (Fig. 5). The extent of divergence between these SIVgor
and HIV-1 strains (i.e., 9.2%, 5.6%, and 18% in Gag, Pol, and
Env proteins, respectively) is similar to the distances observed
between HIV-1 groups M and N and their respective closest
SIVcpzPtt relatives (4, 5). In contrast, the position of the BQID2
strain varied substantially and significantly among phylogenies
derived from different genomic regions; recombination analyses
suggested seven distinct regions, reflecting at least three, or
perhaps four, different evolutionary histories (Fig. 5). For more
than 70% of the genome, including gag, parts of pol (encoding
the protease, the reverse transcriptase, and part of the integrase),
the accessory genes (vif, vpr, and vpu), the 3′ end of env (gp41),
and the nef gene, BQID2 was closely related to HIV-1 group O
(Fig. 5A; trees a, c, and g). For a short region within pol, and for
much of env, BQID2 clustered with other SIVgor strains, with
the precise relationships varying among regions (Fig. 5A; trees
b and d–f). These results indicate that the BQID2 genome rep-
resents a complex recombinant of multiple diverse SIVgor line-
ages, one of which is very closely related to HIV-1 group O. We
calculated the overall genetic distance of HIV-1 group O from
SIVgor-BQID2 by examining only genomic regions that clus-
tered. The distances (0.161–0.172) were similar to those dis-
tances observed for the same genomic regions between HIV-1
group M (0.249–0.268) or group N (0.156–0.156) and their
closest SIVcpz relatives.
A B C
Fig. 3. Evolutionary relationships across SIVcpz, SIVgor, and HIV-1 strains based on partial gene sequences. Phylogenetic trees were constructed using partial
gag (A), pol (B), and env (C) sequences. Newly identified SIVgor strains (highlighted in green boxes) are compared with previously characterized SIVgor
(green), SIVcpzPtt (blue), SIVcpzPts (orange), and HIV-1 (red) strains. Asterisks above branches correspond to nodes supported by bootstrap values over 70%
from ML analyses and posterior probabilities over 0.90 from Bayesian analyses. (Scale bar: number of substitutions per site.)
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Overall, the analysis of full-length SIVgor genomes provided
evidence for three distinct SIVgor clades: one comprising viruses
from site CP in southwest Cameroon, a second comprising
viruses from site BP in western Cameroon, and a third repre-
sented by the virus from site BQ in south-central Cameroon. The
close relationships of HIV-1 groups P and O to the BP and BQ
strains of SIVgor, respectively, indicate that gorillas were the
source of both HIV-1 clades, and point to likely geographic
locations of the cross-species transmission events.
Resistance of Gorilla APOBEC3G to SIVcpz Vif-Mediated Degradation.
Although each of the four groups of HIV-1 resulted from a dif-
ferent cross-species transmission event, all known SIVgor strains,
including the nine strains newly characterized here, form a
monophyletic lineage within the SIVcpz radiation. Thus, SIVgor
appears to have resulted from a single initial transmission event,
which is surprising, given that central chimpanzees and western
gorillas are sympatric over a large area and SIVcpz infection is
widespread among central chimpanzees (4, 5). Furthermore,
although SIVcpz is similarly common among eastern chimpan-
zees (6), we have found no evidence of transmission to sympatric
eastern gorillas. This raised the question of whether host re-
striction factors are limiting chimpanzee-to-gorilla transmission.
One potential restriction factor is APOBEC3G (A3G), which is
normally counteracted by the Vif protein of HIV-1 and SIVcpz,
leading to its degradation. However, we had previously observed
that a Pro (P)-to-Gln (Q) change at site 129 in the gorilla A3G
protein confers resistance to Vif-mediated degradation by some
HIV-1 and SIVcpz strains (19). To examine this result further,
we tested the anti-A3G activity of a larger panel of Vif proteins
from both SIVcpzPtt (from P. t. troglodytes) and SIVcpzPts (from
P. t. scheinfurthii) strains. Specifically, we transfected 293T cells
with a Vif-minus (NL4-3 ΔVif) HIV-1 molecular clone, as well
as increasing amounts of WT chimpanzee (129P), WT gorilla
(129Q), or mutant gorilla (Q129P) A3G-expressing plasmids in
the presence of different SIVcpz and SIVgor Vif variants, and
then determined the effect on viral infectivity and A3G degra-
dation (Fig. 6). The results show that only SIVgor Vif was able to
counteract gorilla A3G efficiently, whereas the Vif proteins from
eight different SIVcpz strains were inactive or only minimally
active (Fig. 6A). This was the case despite the fact that these
same SIVcpz Vif proteins were fully active against the chim-
panzee A3G (Fig. 6B). Most importantly, replacing the Q at
position 129 with a P rendered the gorilla A3G protein com-
pletely sensitive to all Vif variants tested (Fig. 6C), indicating
that the difference in susceptibility was controlled by a single
residue. Western blots of transfected 293T cell lysates confirmed
these results, showing that the gorilla A3G was only efficiently
degraded in the presence of the SIVgor Vif, and not the various
SIVcpz Vif variants (Fig. 6A, Right), whereas chimpanzee and
mutant gorilla A3G was efficiently degraded by all Vif proteins
(Fig. 6 B and C, Right). Using a much larger set of SIVcpz strains,
we thus confirmed that gorilla A3G is resistant to SIVcpz Vif-
mediated degradation, resulting in potent viral restriction. To
ensure that the gorilla gene used for the analyses in Fig. 6 did not
represent an unusual A3G variant, we used PCR to amplify exon
3 of the A3G gene from four additional SIVgor-positive fecal
samples (one from each of the BP, BQ, DJ, and CP sites; Fig. 1).
The results revealed that the four SIVgor-infected gorillas were
all homozygous for a Q codon at position 129 of their A3G gene.
Discussion
Cross-species transmissions of SIVcpz from chimpanzees have
given rise to SIVgor in gorillas and HIV-1 in humans. Com-
paratively little is known about SIVgor; thus, we investigated its
prevalence, host range, geographic distribution, and genetic di-
versity. Our results indicate that SIVgor is much less common
and widespread than SIVcpz in chimpanzees, with infection
A B C
Fig. 4. Evolutionary relationships across SIVcpz, SIVgor, and HIV-1 strains based on full-length protein sequences. Phylogenetic trees were constructed using
complete Gag (A), Pol (B), and concatenated Env and Nef (C) protein sequences. Full-length genome sequences were obtained for SIVgor-BPID1, SIVgor-
BPID15, and SIVgor-BQID2; complete gag and pol sequences were obtained for SIVgor-BPID2; and a complete pol sequence was obtained for SIVgor-BPID3.
Other details are provided in Fig. 3.
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restricted to a small fraction of communities of western lowland
gorillas in southern Cameroon. Moreover, there is only evidence
for a single chimpanzee-to-gorilla transmission event. Nonethe-
less, SIVgor strains exhibit considerable genetic diversity, in-
dicating that this virus has infected gorillas for longer than HIV-1
has infected humans. Most interestingly, among the newly char-
acterized strains, we identified two distinct SIVgor lineages that
are very closely related to HIV-1 groups O and P, indicating
that gorillas were the immediate source of both of these
human viruses.
SIVgor in Gorillas Is Less Common and Widespread than SIVcpz in
Chimpanzees. Gorillas are classified into two species, eastern
and western, that are estimated to have split about 100,000 y ago
(20); both comprise two subspecies: western lowland (Gorilla
gorilla gorilla) and Cross River (Gorilla gorilla diehli) gorillas in
west-central Africa and eastern lowland (G. beringei graueri) and
mountain (G. b. beringei) gorillas in east-central Africa (21).
Eastern and western lowland gorillas are sympatric with eastern
and central chimpanzees, respectively, and both chimpanzee
subspecies are commonly and widely infected with SIVcpz.
However, we have found evidence of SIVgor infection only in
western lowland gorillas. We tested more than 100 (n = 115)
mountain gorillas at two different field sites (Table S2) from
a population that is thought to number now only about 900
individuals (22), and we found all to be SIVgor-negative. Simi-
larly, we found no evidence of SIVgor infection in eastern low-
land gorillas in this and a previous study (16). Finally, a previous
survey of Cross River gorillas in northwest Cameroon also failed
to identify SIVgor infection, although only a small number of
samples were examined (16). Thus, combining all data, we have
screened a total of 5,793 samples from ∼2,500 western and 250
eastern gorillas at 55 different field sites, covering a large pro-
portion of the geographic range of both species (Fig. 1); yet, we
identified SIVgor-positive gorillas only at six sites, all located in
southern Cameroon.
Overall, we found fewer than 2% of western lowland gorillas
to be infected with SIVgor, which is much lower than the esti-
mates of SIVcpz infection rates for central (6%) or eastern
(13%) chimpanzees (4, 6, 16). Although it is possible that some
fecal samples were too degraded to yield positive results, this
possibility alone cannot explain the low SIVgor detection rates in
western gorillas or the lack of infection in eastern gorillas. The
INNO-LIA assay is highly cross-reactive and has detected anti-
bodies from divergent SIV infections in the past (2). Thus, it is
unlikely that lack of cross-reactivity resulted in false-negative
results for large numbers of gorillas, including individuals that
may have acquired more divergent SIVcpzPts strains. Indeed, in
a previous study (16), we used a Western blot approach that
detects both SIVcpzPtt and SIVcpzPts infections with high (92%)
sensitivity (4, 6) to screen eastern gorillas and also failed to de-
tect SIVgor infection. Finally, 236 INNO-LIA–negative samples
from four sites where SIVgor was detected, as well as from seven
sites where SIVgor was absent, were all RT-qPCR–negative.
Thus, it is unlikely that methodological differences or technical
shortcomings have led to a gross underestimation of the preva-
lence and distribution of SIVgor infections.
As previously shown for SIVcpz-infected chimpanzees, SIVgor
infection rates varied considerably among field sites, with some
gorilla communities reaching prevalences of 20% or higher (16,
17). Moreover, within two nesting groups, up to 40% of group
members were infected, indicating efficient spread between
individuals belonging to the same social unit. Interesting, gorillas
from the same field site (BP) that did not belong to these social
A
B
Fig. 5. Mosaic genome structure of SIVgor-BQID2. (A) Phylogenies are shown for seven genomic regions (a–f) indicated below the genome diagram in B.
Genomic regions in which SIVgor-BQID2 clusters with HIV-1 group O, or with SIVgor from site CP, are shown in red and dark green, respectively. (B) In two
other regions (light green), BQID2 is not specifically closely related to other strains. Bootstrap values over 70% from ML analyses are shown with an asterisk.
(Scale bar: number of substitutions per site.)
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groups, were not SIVgor-infected, suggesting that group inter-
actions (or lack thereof) play an important role in inter-
community virus spread. In general, the observations of varying
prevalence rates between different primate species is not sur-
prising; for example, at least 50% of sooty mangabeys (Cerco-
cebus atys), red-capped mangabeys (Cercocebus torquatus), and
western red colobus monkeys (Piliocolobus badius) are infected
with SIV, compared with only about 1% of greater spot-nosed
monkeys (Cercopithecus nictitans) or mustached monkeys
(C. cephus) (2).
SIVgor Infection in Gorillas Is Restricted to Southern Cameroon. Al-
though high prevalence rates within certain gorilla social groups
may reflect transmissions from acutely infected mating partners,
who are likely more infectious than chronically infected indi-
viduals (23), the geographic distribution of SIVgor is neverthe-
less puzzling. Confirmed infections in western lowland gorillas
are spread over a distance of at least 400 km but are restricted to
the northern part of their range in southern Cameroon (Fig. 1).
It is unclear whether the current distribution is related to geo-
graphic barriers or whether it is perhaps the consequence of an
overall population decline. Over recent decades, the number of
wild-living gorilla populations, some of which may have harbored
SIVgor, has declined rapidly because of increased human pres-
ence, hunting, and habitat loss due to deforestation, as well as
infectious disease outbreaks, including Ebola (24, 25). It is also
possible that SIVgor is pathogenic in gorillas, because SIVcpz
infection is in chimpanzees (23, 26). Thus, SIVgor could have
once been present across a larger geographic area but may have
led to the extinction of certain gorilla populations. SIVcpz has
been shown to have a substantive negative impact on the health,
reproduction, and survival of chimpanzees in the wild, and has
caused the decline of at least one chimpanzee community (25,
27). Thus, studies on additional infected and uninfected gorilla
populations are required to determine the impact of SIVgor on
gorilla survival (17). Alternatively, it is possible that following its
introduction, SIVgor may have not yet spread beyond southern
Cameroon. The home ranges of gorilla groups are small com-
pared with chimpanzees, and their movements, as inferred from
gene flow, are influenced by both major and smaller rivers, per-
haps more so than the migration of chimpanzees (28–30). It has
been estimated that SIVgor sequence distances reflect at least
100–200 y of diversification (15). The date of the most recent
common ancestor of SIVgor could be much older than this esti-
mate, given the apparent time dependence of lentivirus molecular
clocks (31, 32). Nonetheless, it is possible that the introduction of
SIVgor into gorillas has been too recent for this infection to have
spread to a larger geographic area.
SIVgor Resulted from a Single Introduction of SIVcpz from Sympatric
Chimpanzees. All newly characterized SIVgor sequences fall
within the previously identified radiation of SIVgor strains, in-
dicating that SIVgor has emerged only once. Chimpanzees and
gorillas have overlapping habitats and often feed in the same
fruit trees (33–35). Sharing the same habitat leads to direct
and indirect contacts, which have resulted in the cross-species
transmission of other pathogens, such as the agents of anthrax,
Ebola, and hepatitis B (15, 36–38). Transmission of SIV would
require physical encounters between the two species, possibly
involving biting or other contact with infected blood or body
fluids. Although such incidences have not been reported, they
would need to occur only rarely to allow SIV transmission. We
thus reasoned that other factors are likely responsible for the
apparently low rate of transmission between these sympatric
species. Previous studies have highlighted the importance of host
restriction factors as a barrier to SIV cross-species transmission
(39). Among these host restriction factors, A3G has been
reported to be one of the most effective (40–42). In fact, gorilla
A3G is resistant to HIV-1 and SIVcpz Vif proteins (Fig. 6),
providing a possible explanation for why SIVcpz has not crossed
between chimpanzees and gorillas more often. Although all
gorillas we have examined are homozygous at the site in A3G
conferring resistance to SIVcpz, extensive A3G sequence diversity
has been observed in other primate species (e.g., rhesus macaques,
sooty mangabeys, African green monkeys) (40, 41). A3G poly-
morphism could render certain individuals more susceptible to
transmissions of SIVcpz, allowing the virus to gain a foothold in
gorillas (19). It is also possible that the spread of SIVgor selected
Fig. 6. Gorilla A3G is resistant to degradation by SIVcpz but not SIVgor Vif proteins. Plasmids expressing vif genes from SIVcpzPtt (red), SIVcpzPts (blue), and
SIVgor (green) were cotransfected with increasing quantities (0, 25, 50, and 100 ng) of WT gorilla A3G (A), WT chimpanzee A3G (B), and the gorilla A3G
mutant Q129P (C), along with a vif-deficient HIV-1 molecular clone (NL4-3 ΔVif) into 293T cells. Two days after transfection, viral supernatants were used
to infect TZM-bl reporter cells (a HeLa-derived cell line that constitutively expresses CD4, CCR5, and CXCR4 cell surface receptors) and infectious particle
release was measured. (Upper) Virus infectivity (y axis) plotted in the presence of increasing quantities (x axis) of the various Vif expression plasmids (in-
fectivity in the absence of Vif is shown in black) is depicted. Values represent averages (with SDs) from three different transfections. (Lower) Western blots of
the corresponding 293T cell lysates (transfected with 50 ng of A3G), probed for A3G and Vif expression (GAPDH represents the loading control), are depicted.
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for an increased frequency of the A3G 129Q mutation in gorillas,
but we note that 129Q is also found in eastern gorillas (20), which
are not naturally SIVgor-infected, suggesting that this mutation
spread before the divergence of the two species.
SIVgor from Gorillas Is the Precursor of HIV-1 Groups O and P in
Humans. A total of 56 SIVgor-infected gorillas have now been
identified in this and previous studies. Partial env or pol
sequences have been obtained for about half of them (9, 16, 17),
although only small subgenomic fragments were amplified for
most cases. Nonetheless, available sequences indicate greater
similarity among SIVgor strains from the same field site than
among strains from different field sites. Phylogeographic clus-
tering was particularly evident at the BP site, where all seven
viruses form a distinct clade (Fig. 3). HIV-1 group P viruses fall
within the radiation of the SIVgor strains from site BP, strongly
suggesting that this rare form of HIV-1 originated in this region
of western Cameroon.
The newly characterized SIVgor strain from site BQ re-
solves the question of whether HIV-1 group O resulted from
a chimpanzee-to-human or gorilla-to-human transmission (1).
SIVgor-BQID2 is closely related to HIV-1 group O viruses
across most of its genome, and its phylogenetic position (Fig. 5)
indicates that this lineage was transmitted from chimpanzees to
gorillas before the onward transmission to humans. The mosaic
nature of the SIVgor-BQID2 genome indicates that at some
point in the past, prevalence rates must have been sufficiently
high to allow coinfection of the same individual with diverse
SIVgor lineages. Although we cannot be precise about the lo-
cation of the source population of HIV-1 group O, we can
conclude that gorillas transmitted SIVgor to humans on at least
two occasions.
SIVgor Has Adapted to Spread Efficiently in the Human Population.
The four HIV-1 groups have different virological and epidemi-
ological histories. Only HIV-1 group M spread globally and is
responsible for the current HIV-1 pandemic. Infections with
group N and P strains are very rare and largely restricted to
Cameroon (43), but group O is the second most widespread
HIV-1 lineage. Group O viruses, which currently account for up
to 1% of all HIV-1 infections in Cameroon (44), also spread to
other countries, including some outside of Africa. Indeed, the
earliest (albeit retrospectively) documented AIDS cases in
Europe were identified in a Norwegian sailor and his family, who
became infected in the 1960s with viruses later shown to be
group O (45). Group O infections are most prevalent in west and
central Africa. In addition to Cameroon, group O viruses have
been found in Chad, Gabon, Niger, Nigeria, Senegal, and Togo
(13). In Nigeria, group O reactive sera were detected in about
1% of HIV-positive samples (13). Because of the size of the
AIDS epidemic in that country, this finding extrapolates to tens
of thousands of group O infections in Nigeria alone. The natural
history of group O infection appears to be similar to the natural
history of group M infection (43), and it is thus likely that
a roughly similar number of people have died as are currently
infected. Therefore, it is reasonable to estimate that HIV-1
group O may have infected around 100,000 people (14).
Efficient spread of a zoonotic pathogen in the human pop-
ulation depends on a combination of viral, host, and environ-
mental factors. The most recent common ancestors of HIV-1
groups M and O are both estimated to have existed around 1920
(46, 47), whereas the lower levels of diversity seen in group N,
and especially in group P, indicate that they emerged more re-
cently. Coalescent studies suggest that groups O and M un-
derwent similar rates of exponential growth until about 1960, and
only since then has the spread of group M far outstripped the
spread of group O (47). Importantly, groups M and O have
undergone independent adaptations to the human host. In both
lineages, Met at position 30 in the Gag matrix protein was
replaced by a basic residue, Arg (48), which enhances viral
replication in human lymphoid tissue (49). Both lineages also
had to acquire resistance to the potent restriction factor tetherin:
SIVcpz and SIVgor antagonize tetherin via their Nef proteins,
but the tetherin motif that these proteins target was deleted in
a human ancestor. In group M viruses, Vpu adapted to acquire
antitetherin activity (50), whereas in the ancestor of group O, the
Nef protein evolved to use a different target within tetherin (14).
The fact that group O viruses have not spread even more widely
in the human population is thus unlikely to be due to a lack of
adaptation to the human host, but may simply reflect the absence
of epidemiological opportunity during the early stages of the
pandemic expansion of AIDS starting a little over 50 y ago.
Clearly, SIVs from both chimpanzees and gorillas have the capacity
to spread efficiently in the human host. Thus, it will be important to
continue to monitor humans for primate lentiviruses and to study
the viral and host factors that govern cross-species infection and
onward transmission.
Materials and Methods
Sample Collection and Study Sites. Fecal samples were collected between July
2009 and June 2013 from wild western lowland gorillas (G. g. gorilla) in
Cameroon and Gabon, eastern lowland gorillas (G. beringei graueri) in the
DRC, and mountain gorillas (G. b. beringei) in the DRC and Uganda. Most
samples were collected around night nests and feeding sites, but also op-
portunistically (16, 17, 22, 51). Samples were preserved in RNAlater
(Ambion), kept at ambient temperature in the field for a maximum of 3 wk
and then stored at −20 °C or −80 °C. Field information included the global
positioning system position and condition of fecal samples, as well as the
number and age of gorilla nests.
Noninvasive Detection of SIVgor. All gorilla fecal samples were first tested
for the presence of HIV-1 cross-reactive antibodies using the INNO-LIA HIV I/II
score confirmation test (Innogenetics) as previously described (9, 16). An
RT-qPCR assay, previously shown to detect HIV-1 groups M, N, O, and P;
SIVcpzPtt; SIVcpzPts; and SIVgor in fecal samples (18), was used to screen all
antibody-positive, as well as some antibody-negative, fecal samples. Viral
RNA was extracted using the NucliSens Magnetic Extraction Kit (BioMerieux)
(17). To characterize individual SIVgor strains, nested RT-PCR was used to
amplify partial env (315–692 bp) and pol (285 bp) sequences (4, 9, 15–17). In
addition, diagnostic gp41 (155 bp) and gag (408 bp) fragments were am-
plified using newly designed primer sets (Table S3). To confirm their species
origin, antibody-positive samples and a subset of negative samples were
subjected to mitochondrial 12S sequence analyses (9, 52). To determine the
number of sampled individuals, microsatellite analysis was performed on all
samples collected at the same nesting sites. Gorilla group sizes were esti-
mated based on the number of night nests (53). Fecal samples collected less
than 20 m from the nests were considered to belong to the same group (16,
17). Samples were genotyped at seven loci using multiplex PCR (D18s536,
D4s243, D10s676, D9s922 and D2s1326, D2s1333, D4s1627). For gender de-
termination, a region of the amelogenin gene was amplified (4). Homozy-
gous loci were amplified at least four times to minimize allelic dropout.
Matching samples were given a consensus identification number and ge-
notype (Table S2).
SIVgor Prevalence. SIVgor prevalence rates were estimated for each field
site based on the proportion of SIVgor-positive gorillas as determined by
microsatellite analysis, taking into account repeated sampling per mission
and on consecutive missions. Previous studies of western and eastern lowland
gorillas indicated that each individual was sampled ∼1.8 and 1.9 times, re-
spectively, and that a maximum of 50% of animals were resampled on
consecutive missions (16, 17, 51). The prevalence was thus calculated by
multiplying the number of samples with the coefficient [(n × 1.8)/(1 +
(n − 1) × 0.50], with n representing the number of missions; 95% confi-
dence limits were calculated as described (ww3.ac-poitiers.fr/math/prof/resso/
cali/ic_phrek.html) (54).
Generation of Full-Length SIVgor Sequences. Whole-genome sequences of
SIVgor were generated by amplifying partially overlapping subgenomic
fragments from fecal viral RNA as previously described (4, 5, 15). Ambiguous
sites in sequence chromatograms were resolved as reported (4, 5, 15).
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Phylogenetic Analyses. Nucleotide and protein sequences were aligned using
Muscle (55) and the online version of MAFFT (mafft.cbrc.jp/alignment/server/)
with minor manual adjustments. Sites that could not be unambiguously
aligned were automatically (Gblocks; phylogeny.lirmm.fr/phylo_cgi/index.
cgi) excluded and manually checked. Proteome sequences were generated
by joining deduced Gag, Pol, Env, and Nef amino acid sequences; the car-
boxy termini of Gag sequences that overlapped with Pol sequences were
excluded. Newly derived partial and full-length SIVgor sequences were
compared with previously published SIVgor; SIVcpz; and HIV-1 group M, N,
O, and P reference sequences. Phylogenies were inferred using maximum
likelihood (ML) and Bayesian methods. ML trees were constructed using
PhyML version 3.1 for nucleotide sequence and version LG4X for amino
acid sequences, and branch support was evaluated with 1,000 bootstrap
replicates for each tree (56, 57); only values higher than 70% were consid-
ered meaningful. Bayesian inference of phylogeny was performed using
MrBayes3.2 (58). For nucleotide alignments, 10,000 trees were sampled with
Markov Chain Monte Carlo (MCMC) algorithms under the GTR + G + I model
with six rate categories within two runs totaling 20,000,000 generations.
Estimated sample sizes for all parameters were >200, indicating that the two
runs converged. For protein alignments, a mixed model of amino acid
substitution was used and MCMC runs were performed until the runs
converged (10–20 million generations). For both nucleotide and protein
alignments, the burn-in was set to 25%. Posterior probabilities ≥0.95 were
considered significant.
Recombination Analysis. Full-length SIVgor sequences were analyzed using
bootscan and similarity plots with SimPlot version 3.5.1 and Recco version 0.93
(59, 60). Bootscan analyses examined neighbor-joining trees with a 400-bp
window and 20-bp increments. Breakpoints were inferred using SimPlot
and Recco, and verified by visual inspection. The recombinant patterns
were subsequently confirmed by phylogenetic tree analysis of nucleotide
sequences using ML methods implemented in PhyML version 3.1 (56). Branch
support was evaluated with the nonparametric bootstrap method, and
1,000 bootstrap replicates were performed for each tree. Only values higher
than 70% were considered significant.
Resistance Testing of Gorilla A3G to Degradation by SIVcpz and SIVgor Vif.
A ΔVif replication-competent molecular clone (NL4-3) was obtained from
the AIDS Research and Reference Reagent Program. C-terminally FLAG-tagged
expression plasmids of SIVcpzPts (TAN1 and TAN2), SIVcpzPtt (EK505 and
LB715), and SIVgor (CP2139) vif genes; a ΔVif-GFP control construct; and HA-
tagged chimpanzee and gorilla A3G expression plasmids have been de-
scribed (19). Vif alleles from SIVcpzPtt MT145 (4), SIVcpzPtt GAB2 (61, 62),
SIVcpzPts TAN3 (63), and SIVcpzPts TAN13 (63) were amplified from full-
length molecular clones and cloned into the pCRV1 Vif-expression plasmid
(19). Increasing amounts of HA-tagged A3G (0, 25, 50, and 100 ng) and
Vif-expression (or ΔVif-GFP for control) plasmids (50 ng) were cotransfected
with NL4-3 ΔVif (500 ng) in 293T cells. The total amount of DNA for each
transfection was kept identical by substituting the A3G-expression plasmid
with a GFP-expression plasmid. Supernatants were collected 48 h after
transfection and used to infect 1 × 104 TZM-bl cells in 96-well plates, and
infectivity was assessed by measuring β-gal activity (Applied Biosystems).
Average relative infectivity values and SDs were calculated using data from
three independent transfections. For A3G degradation analysis, transfected
293T cells were lysed, separated on 10% SDS-polyacrylamide gels (Invi-
trogen), transferred to PVDF membranes (Pierce), and probed with rabbit
anti-HA polyclonal (Sigma) and rabbit anti-FLAG monoclonal (Sigma) anti-
sera. GAPDH was detected with a mouse primary antibody (Santa Cruz
Biotechnology). Membranes were incubated with HRP-conjugated second-
ary antibodies (Sigma), developed with SuperSignal West Femto (Pierce),
and detected using a FluorChem E imaging system (Protein Simple).
GenBank Accession Numbers. Full-length and partial SIVgor sequences are
available under GenBank accession nos. KP004989–KP004991 and KP004992–
KP004999, respectively.
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